Firialta Drug Interactions

CYP3A4 Inhibitors and Inducers: Strong CYP3A4 Inhibitors: Firialta is a CYP3A4 substrate. Concomitant use with a strong CYP3A4 inhibitor increases finerenone exposure [see PHARMACOLOGY: Pharmacokinetics under Actions], which may increase the risk of Firialta adverse reactions. Concomitant use of Firialta with strong CYP3A4 inhibitors is contraindicated [see Contraindications]. Avoid concomitant intake of grapefruit or grapefruit juice.
Moderate and Weak CYP3A4 Inhibitors: Firialta is a CYP3A4 substrate. Concomitant use with a moderate or weak CYP3A4 inhibitor increases finerenone exposure [see PHARMACOLOGY: Pharmacokinetics under Actions], which may increase the risk of Firialta adverse reactions. Monitor serum potassium during drug initiation or dosage adjustment of either Firialta or the moderate or weak CYP3A4 inhibitor, and adjust Firialta dosage as appropriate [see Monitoring and Dose Adjustment under Dosage & Administration and Drugs That Affect Serum Potassium as follows].
Strong and Moderate CYP3A4 Inducers: Firialta is a CYP3A4 substrate. Concomitant use of Firialta with a strong or moderate CYP3A4 inducer decreases finerenone exposure [see PHARMACOLOGY: Pharmacokinetics under Actions], which may reduce the efficacy of Firialta. Avoid concomitant use of Firialta with strong or moderate CYP3A4 inducers.
Drugs That Affect Serum Potassium: More frequent serum potassium monitoring is warranted in patients receiving concomitant therapy with drugs or supplements that increase serum potassium. [see Monitoring and Dose Adjustment under Dosage & Administration and Hyperkalemia under Precautions].